For sickle cell patients and families, Oxbryta was supposed to be a lifeline. Instead, it left many worse off–facing new health crises, hospitalizations, and in some cases, unthinkable loss. Now, Oxbryta lawsuits are uncovering what Pfizer knew and when it knew it.
Oxbryta is a prescription drug developed by Global Blood Therapeutics and later acquired by Pfizer. It was voluntarily recalled in September 2024 after new evidence revealed that it caused serious and potentially fatal complications, including vaso-occlusive crises and organ damage.
This page looks at Oxbryta lawsuits and their potential settlement value.
Oxbryta is a prescription drug made by Pfizer that was recalled in September 2024 after evidence revealed that it caused a number of very serious and potentially fatal health problems, including vaso-occlusive crisis and organ damage. Continue reading